(Q41332820)

29 September 2017

title

Modeling therapeutic benefit in the midst of uncertainty: therapy for hepatitis C. (English)

1 reference

29 September 2017

2

S G Pauker

1 reference

29 September 2017

W G Bennett

1

1 reference

29 September 2017

G L Davis

series ordinal

3

1 reference

29 September 2017

J B Wong

series ordinal

4

1 reference

29 September 2017

publication date

1 December 1996

1 reference

Digestive Diseases and Sciences

29 September 2017

published in

1 reference

29 September 2017

volume

41

1 reference

29 September 2017

issue

12 Suppl

1 reference

29 September 2017

page(s)

56S-62S

1 reference

The distinction between cost and charges

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF02087877

Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02087877

Cost and health implications of cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02087877

Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02087877

Cost effectiveness of colorectal cancer screening in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02087877

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

12 December 2020

Hepatocellular carcinoma in Italian patients with cirrhosis

1 reference

12 December 2020

The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C

1 reference

12 December 2020

A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method.

1 reference

12 December 2020

Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal.

1 reference

12 December 2020

A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis

1 reference

12 December 2020

Chronic non-A, non-B hepatitis with special reference to the transfusion-associated form

1 reference

12 December 2020

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

12 December 2020

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

1 reference

12 December 2020

Screening for breast cancer

1 reference

12 December 2020

Therapy for chronic hepatitis C.

1 reference

12 December 2020

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

1 reference

12 December 2020

Markov models in medical decision making: a practical guide.

1 reference

12 December 2020

Screening blood donors for human immunodeficiency virus antibody: cost-benefit analysis

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon

1 reference

12 December 2020

Cost effectiveness of vaccination against pneumococcal pneumonia: an update

1 reference

12 December 2020

Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis

1 reference

12 December 2020

The Markov process in medical prognosis.

1 reference

12 December 2020

A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making.

1 reference

12 December 2020

Natural course of chronic hepatitis C

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02087877

1 reference

29 September 2017

1 reference